G lioblastoma is the most deadly form of brain cancer in adults, and is responsible for more than 12,000 brain-tumour diagnoses in the United States each year 1 . Extensive characterization of its molecular basis, largely made possible through massive genomic studies 2, 3 , has provided a comprehensive understanding of the cancer-causing genes and aberrant pathways that underlie glio blastoma development, relapse and resistance. But putative therapies that target these genes and pathways have shown little efficacy in clinical trials 4 , motivating investigation of alternative targets. On page 355, Miller et al. 5 report results from an elegant, systematic screen, which aimed to identify therapeutic targets for glioblastoma that regulate the epigenome -a collection of heritable chemical modifications that control gene activity without altering the underlying DNA sequence.
Epigenetic modifications include those on DNA (for instance, the presence of methyl groups on cytosine residues), and those on histone proteins (including methylation, acetylation and phosphorylation), around which DNA is packaged. Collectively, these modifications dictate whether genes are expressed or silent, typically in a cell-typespecific manner. Enzymes called epigenetic modifiers are responsible for establishing, maintaining, reading and removing these modifications in a highly orchestrated, multifaceted manner.
Cancer biologists have taken a keen interest in the role of epigenetic modifiers in tumour development, largely because mutations in the genes that encode these enzymes are prevalent in a wide range of cancers 6 . Various classes of epigenome-targeting drug have created considerable enthusiasm of late, and clinical trials of all phases are under way for such drugs 7 .
Miller et al. sought to investigate the cellular requirements for epigenetic modifiers in glioblastoma (Fig. 1) . The authors used cancerous cells derived from people with glioblastoma, which they either grew in culture or transplanted into the brains of mice. They used these models to perform parallel in vitro and in vivo screens to look for those genes on which cancer cells depend by introducing RNA molecules that inhibit the expression of
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Keeping it real to kill glioblastoma
The results of in vitro and in vivo screens to identify genes that are essential for the survival of a type of brain cancer show almost no overlap, underlining the need for caution when interpreting in vitro studies. See Letter p355.
frequency and a constant phase difference. The latest developments in X-ray sources have aimed to increase coherence to take advantage of the generally hidden phase information contained in the waves and to bring the numerous achievements of optical lasers into the nanoscale world 7 .
In the past decade [8] [9] [10] , X-ray optics have been able to generate 2D images with a spatial resolution of about 10 nm. A technique called tomography can be used to computationally reconstruct 3D objects from sets of these images, which are usually captured from a range of projection angles. This technique is now routinely used in biology 11 and materials science. However, because the spatial resolution is still far from the sub-nanometre wavelength limit of X-rays, researchers have started to develop alternative approaches that are based on X-ray diffraction, rather than reflection or absorption.
Donnelly and colleagues' imaging technique uses such an approach, called X-ray ptychography (Fig. 1a) . The authors demonstrated their technique on a gadolinium cobalt magnetic cylinder that has a 5-µm diameter. They directed a beam of polarized short-wavelength (hard) X-rays at a particular spot on the cylinder and used high-speed detectors to observe the diffraction pattern produced. By scanning the beam across the cylinder and gradually rotating the cylinder, the authors collected a series of such diffraction patterns. They then tilted the cylinder by 30° and repeated the observations -this allowed them to access all three dimensions of magnetization. Finally, the authors applied sophisticated algorithms to reconstruct images of the cylinder's magnetization, enabling them to identify complex spin textures with a spatial resolution of about 100 nm (Fig. 1b) .
Although this resolution is larger than has been achieved using conventional X-ray optics, the authors' technique promises to push the spatial resolution of X-ray imaging to its fundamental limit. This would bypass the technological challenges associated with improving the efficiency and resolution of conventional X-ray optics. Two achievements support this promise. First, a spatial resolution of a few nanometres has been demonstrated in ptychography using long-wavelength (soft) X-rays 12 . Second, hard X-ray ptychographic tom ography was used earlier this year 13 to achieve non-destructive 3D imaging of integrated circuits -albeit without magnetic sensitivity -with a spatial resolution of 14.6 nm. This makes the tool highly attractive for real-world applications, for example in the industrial quality control of nanoscale technological devices.
Donnelly and colleagues' work is a landmark in the development of advanced metrology for magnetic materials, but it has not yet reached its full potential. The main challenge for magnetic X-ray microscopy in the future will be to keep up with the length scales in relevant magnetic devices -in existing devices, such scales are already smaller than the resolution offered by state-of-the-art X-ray ptychography. For comparison, tomography using electron microscopes has imaged 3D structures with single-atom precision 14 . An advantage of magnetic X-ray microscopy over other techniques will be its ability to characterize buried interfaces 15 -particular spins in the regions between materials that have a large and distinct spin-orbit coupling. These spins can generate robust (topologically protected) spin textures that offer improvements in storage capacity, energy efficiency and data-transfer speed with respect to current technologies. Being able to see individual spins flowing in real time through such interfaces sounds like science fiction, but with the prospects of X-ray technologies on the horizon, it might become reality in the near future. ■ particular genes (one RNA in each glio blastoma cell). The authors grew the cells for two to three weeks, and looked for genes whose inhibition caused cell depletion, compared with controls in which the inhibitory RNAs were inactive. Finally, they compared inventories of genes depleted under the two experimental conditions. Surprisingly, the researchers found that the candidate gene classes identified differed vastly between experiments, with only three genes picked out under both conditions. Cells grown in culture, where the nutrients required for tumour-cell proliferation are abundant, depended on genes encoding epigenetic modifiers that regulate cell metabolism and macromolecule production. By contrast, cells propagated in mice depended on a class of gene that encodes epigenetic modifiers involved in the regulation of transcriptional pause release -a mechanism by which gene transcription is restarted after a pause. Epigenetic modification of transcriptional pause release allows the timing, rate and magnitude of transcriptional responses to be highly coordinated under certain physiological conditions 8 . The targets of this class of modifier include stressresponse genes, and the authors suggest that activation of these genes enables tumour cells in vivo to adapt to the harsh conditions of their microenvironment.
Peter Fischer is in the Materials
Among the top hits emerging from the in vivo dependency screen was the gene Jumonji C-domain-containing protein 6 (JMJD6), which encodes a bifunctional enzyme that can modify molecules by removing specific methyl groups or adding hydroxyl groups. Miller et al. demonstrated that the JMJD6 protein binds to active regulatory DNA sequences that control the expression of stressresponse genes in their glioblastoma models. Epigenetic modification by JMJD6 involves 9 coordination of transcriptional pause release, promoting gene transcription; presumably, activation of stress-response genes by JMJD6 promotes tumour-cell survival. Targeted inhibition of JMJD6 or related factors reproducibly prolonged the survival of mice with glioblastomas, but had no detectable effect on glioblastoma cells in culture.
The authors' results have implications that extend far beyond the specifics of the current report. The overwhelming majority of similar dependency screens reported in the literature were conducted in vitro. Most use cancer-cell lines that were established decades ago and propagated in standard tissue-culture conditions, which involve nutrient-containing culture medium mixed with growth-factorcontaining serum. In the current study, the in vitro screen used patient-derived cells grown under serum-free conditions -conditions that are arguably more faithful, physiologically, to the real-life conditions in which tumours grow -and still showed little overlap with the in vivo results.
This lack of congruence raises serious concerns about the validity of results obtained using standard in vitro approaches, even if such results have subsequently been reproduced in other cell lines. Similar context-dependent readouts have been observed in other in vivo dependency studies 10, 11 , underlining the need for careful consideration of the experimental system used when conducting such screens.
Miller and co-workers' findings add to a growing list of potential epigenetic therapies for cancer. Drugs that inhibit the activity of proteins of the BET family of epigenetic modifiers have yielded promising results across a range of cancers and are now being evaluated in early clinical trials 12, 13 . Among those causing the biggest stir are drugs that target BRD4, which (in addition to other roles) functions in concert with JMJD6 to regulate transcriptional pause release. BRD4 inhibitors have shown preliminary efficacy in glioblastoma cells and mouse models 14, 15 
